NexPlasmaGen New Board Member
Montreal / August 21, 2025 - NexPlasmaGen is pleased to announce that Mr. Suman Mallick has joined NexPlasmaGen board! Suman Mallick is a Managing...
22 August, 2025
/ 0 Comments
Masonry
NexPlasmaGen Secures Patent in South Korea
Montreal / July 24, 2025 – NexPlasmaGen is proud to announce that it has secured a patent in South Korea to protect its...
24 July, 2025
/ 0 Comments
Clinical trials protocol published in BMC Cancer journal
Montreal / April 25, 2025 – Clinical researchers at the University of Montreal Hospital Center (CHUM) have published in the journal BMC Cancer the...
25 April, 2025
/ 0 Comments
Safety clinical trials with NexPlasmaGen’s technology start!
March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen medical technology Montreal / March 08, 2025...
08 March, 2025
/ 0 Comments
NexPlasmaGen wins a Corporate Livewire Innovation & Excellence Award
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The...
19 September, 2024
/ 0 Comments
NexPlasmaGen’s New Board Director and New Advisor
Montreal / August 8, 2024 - NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen! David...
08 August, 2024
/ 0 Comments
Best MedTech Oncology Business 2024 – Canada
Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada...
19 April, 2024
/ 0 Comments
Second US patent granted
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was...
05 April, 2024
/ 0 Comments
NexPlasmaGen’s new funding for R&D and commercialization
Montreal / October 06, 2023 - NexPlasmaGen received a financial support of $219,500 from Quebec's Ministère de l'économie, de l'innovation et de l'énergie...
06 October, 2023
/ 1 Comment